DK1247097T3 - Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi - Google Patents

Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi

Info

Publication number
DK1247097T3
DK1247097T3 DK01902043T DK01902043T DK1247097T3 DK 1247097 T3 DK1247097 T3 DK 1247097T3 DK 01902043 T DK01902043 T DK 01902043T DK 01902043 T DK01902043 T DK 01902043T DK 1247097 T3 DK1247097 T3 DK 1247097T3
Authority
DK
Denmark
Prior art keywords
determining
cancer therapy
effectiveness
individual
response
Prior art date
Application number
DK01902043T
Other languages
English (en)
Inventor
Sarah S Bacus
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of DK1247097T3 publication Critical patent/DK1247097T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/13—Tracers or tags

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Electrotherapy Devices (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01902043T 2000-01-12 2001-01-12 Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi DK1247097T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17651400P 2000-01-12 2000-01-12
US17651500P 2000-01-12 2000-01-12
EP01902043A EP1247097B1 (en) 2000-01-12 2001-01-12 Method for determining the efficacy of cancer therapy

Publications (1)

Publication Number Publication Date
DK1247097T3 true DK1247097T3 (da) 2004-11-29

Family

ID=26872320

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01902043T DK1247097T3 (da) 2000-01-12 2001-01-12 Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi

Country Status (10)

Country Link
US (2) US6962789B2 (da)
EP (2) EP1247098A1 (da)
JP (2) JP2003519796A (da)
AT (1) ATE271691T1 (da)
AU (2) AU2951801A (da)
CA (2) CA2397772C (da)
DE (1) DE60104392T2 (da)
DK (1) DK1247097T3 (da)
MX (2) MXPA02006778A (da)
WO (2) WO2001051924A2 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
AU5352901A (en) * 2000-04-14 2001-10-30 Ventana Med Syst Inc Method for quantification of akt protein expression
US20040085443A1 (en) * 2000-12-13 2004-05-06 Kallioniemi Olli P Method and system for processing regions of interest for objects comprising biological material
ATE530635T1 (de) 2001-08-21 2011-11-15 Ventana Med Syst Inc Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status
US20030165263A1 (en) * 2002-02-19 2003-09-04 Hamer Michael J. Histological assessment
GB0218909D0 (en) * 2002-08-15 2002-09-25 Qinetiq Ltd Histological assessment
US7648678B2 (en) 2002-12-20 2010-01-19 Dako Denmark A/S Method and system for pretreatment of tissue slides
GB0229734D0 (en) * 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
CA2526636C (en) * 2003-05-20 2012-10-02 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2005117553A2 (en) * 2004-05-27 2005-12-15 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
CA2600845A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
US7504225B2 (en) 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
US20070091109A1 (en) 2005-09-13 2007-04-26 Roscoe Atkinson Image quality
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
CN104099290A (zh) 2006-10-23 2014-10-15 人类起源公司 用胎盘细胞群治疗骨缺损的方法和组合物
ES2465465T3 (es) 2006-11-01 2014-06-05 Ventana Medical Systems, Inc. Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
US9697582B2 (en) 2006-11-16 2017-07-04 Visiopharm A/S Methods for obtaining and analyzing images
JP2010518812A (ja) 2007-02-12 2010-06-03 アンスロジェネシス コーポレーション 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
US9355445B2 (en) 2007-03-01 2016-05-31 Nec Corporation Breast cancer pathological image diagnosis support system, breast cancer pathological image diagnosis support method, and recording medium recording breast cancer pathological image diagnosis support program
CA2687178C (en) 2007-05-23 2014-02-04 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
KR101573026B1 (ko) 2007-07-25 2015-11-30 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료에서 이용하기 위한 멀티키나아제 억제제
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
US20090170925A1 (en) * 2007-10-29 2009-07-02 Eisai R&D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
CA2979353C (en) 2008-06-05 2020-06-30 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
EP2327040B1 (en) 2008-08-15 2013-12-18 Visiopharm A/s A method and a system for determining a target in a biological sample by image analysis
AU2009283161A1 (en) 2008-08-22 2010-02-25 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
GB2464747B (en) * 2008-10-10 2013-05-15 Hai Kang Life Corp Ltd Method for detection of analyte in microarray of samples and apparatus for performing such method
US8349574B2 (en) * 2009-01-15 2013-01-08 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of Her-3
JP2012519290A (ja) 2009-03-04 2012-08-23 エフ．ホフマン−ラ ロシュ アーゲー 肺の扁平上皮癌のためのマーカーとしてのセルピンｂ１３
WO2010141543A1 (en) * 2009-06-02 2010-12-09 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
NZ619359A (en) 2009-07-02 2015-07-31 Anthrogenesis Corp Method of producing erythrocytes without feeder cells
JP5490568B2 (ja) * 2010-02-26 2014-05-14 オリンパス株式会社 顕微鏡システム、標本観察方法およびプログラム
US8562973B2 (en) 2010-04-08 2013-10-22 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
AU2011352036A1 (en) 2010-12-31 2013-07-18 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
WO2012100190A2 (en) * 2011-01-21 2012-07-26 Carnegie Mellon University Identifying location biomarkers
CN113559126A (zh) 2011-06-01 2021-10-29 人类起源公司 利用胎盘干细胞治疗疼痛
US20130338014A1 (en) * 2012-04-05 2013-12-19 Vala Sciences, Inc. Calibration Standards For Digital Histocytometry
WO2013192457A1 (en) * 2012-06-20 2013-12-27 Merrimack Pharmaceuticals, Inc. Marker quantitation in single cells in tissue sections
ES2743458T5 (es) 2014-08-08 2023-06-08 Us Health Eliminación fotocontrolada de dianas in vitro e in vivo
US10304188B1 (en) 2015-03-27 2019-05-28 Caleb J. Kumar Apparatus and method for automated cell analysis
EP3331909A1 (en) 2015-08-07 2018-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near infrared photoimmunotherapy (nir-pit) of suppressor cells to treat cancer
CN114681623A (zh) 2015-08-18 2022-07-01 乐天医药生技股份有限公司 酞菁染料偶联物的制造方法及稳定偶联物
CN108136039A (zh) 2015-08-18 2018-06-08 阿斯皮利安治疗学股份有限公司 用于光免疫疗法的组合物、联用及相关方法
EP3559721B1 (en) * 2016-12-23 2021-09-15 Bio-Rad Laboratories, Inc. Reduction of background signal in blot images
JPWO2018207361A1 (ja) * 2017-05-12 2020-03-12 オリンパス株式会社 細胞画像取得装置

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086476A (en) 1985-11-04 1992-02-04 Cell Analysis Systems, Inc. Method and apparatus for determining a proliferation index of a cell sample
US5008185A (en) 1985-11-04 1991-04-16 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear proteins
US4741043B1 (en) * 1985-11-04 1994-08-09 Cell Analysis Systems Inc Method of and apparatus for image analyses of biological specimens
US5109429A (en) 1985-11-04 1992-04-28 Cell Analysis Systems,Inc. Apparatus and method for analyses of biological specimens
US5202931A (en) * 1987-10-06 1993-04-13 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear protein
US5389523A (en) * 1988-05-31 1995-02-14 The United States Of Americas, As Represented By The Secretary Of Commerce Liposome immunoanalysis by flow injection assay
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0378383A3 (en) * 1989-01-10 1991-09-11 ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA Method and device for detection, validation and quantitation of multiple-drug resistance-associated antigens
US5784162A (en) * 1993-08-18 1998-07-21 Applied Spectral Imaging Ltd. Spectral bio-imaging methods for biological research, medical diagnostics and therapy
DE69228300T2 (de) * 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
JP3645903B2 (ja) * 1992-03-04 2005-05-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 比較ゲノムハイブリダイゼーション（ｃｇｈ）
CA2094341A1 (en) * 1992-04-28 1993-10-29 Carl W. Porter Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker
US5536642A (en) * 1993-09-09 1996-07-16 Barbera-Guillem; Emilio Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
US5491069A (en) * 1994-02-18 1996-02-13 The Regents Of The University Of California Biomarkers of cell senescence
US6463438B1 (en) * 1994-06-03 2002-10-08 Urocor, Inc. Neural network for cell image analysis for identification of abnormal cells
US5846749A (en) * 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5998151A (en) 1995-12-01 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase
US6165734A (en) * 1995-12-12 2000-12-26 Applied Spectral Imaging Ltd. In-situ method of analyzing cells
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
US5935801A (en) * 1996-03-29 1999-08-10 Dana-Farber Cancer Institute Monoclonal antibody that detects apoptotic antigen
US6447997B1 (en) * 1997-07-18 2002-09-10 Research Development Foundation Gene coding for GADD153 as a clinical diagnostic and prognostic in cancer therapy
DE69840509D1 (de) * 1997-09-30 2009-03-12 Peviva Ab Apoptose-bezogene verbindungen und deren verwendung
AU734226B2 (en) * 1997-11-10 2001-06-07 Regents Of The University Of California, The Biochemical methods for detecting cervical dysplasia and cancer
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6350452B1 (en) * 1998-09-24 2002-02-26 Promega Corporation Apoptosis marker antibodies and methods of use
CA2347002A1 (en) * 1998-10-21 2000-04-27 Steven Jay Smith Protein quantitation with cell imaging densitometry
US6372895B1 (en) * 2000-07-07 2002-04-16 3M Innovative Properties Company Fluorogenic compounds
US20040058320A1 (en) * 2000-12-21 2004-03-25 Roninson Igor B. Reagents and methods for identifying and modulating expression of tumor senescence genes

Also Published As

Publication number Publication date
US20010044124A1 (en) 2001-11-22
AU2788701A (en) 2001-07-24
JP2003519795A (ja) 2003-06-24
DE60104392T2 (de) 2005-08-11
JP2003519796A (ja) 2003-06-24
WO2001051924A2 (en) 2001-07-19
MXPA02006843A (es) 2004-04-05
US6962789B2 (en) 2005-11-08
CA2397772C (en) 2007-06-12
ATE271691T1 (de) 2004-08-15
EP1247098A1 (en) 2002-10-09
AU785347B2 (en) 2007-02-01
EP1247097B1 (en) 2004-07-21
JP3699399B2 (ja) 2005-09-28
DE60104392D1 (de) 2004-08-26
AU2951801A (en) 2001-07-24
CA2397417A1 (en) 2001-07-19
WO2001051924A3 (en) 2002-01-10
MXPA02006778A (es) 2004-04-05
US7833698B2 (en) 2010-11-16
CA2397772A1 (en) 2001-07-19
EP1247097A2 (en) 2002-10-09
WO2001051928A9 (en) 2002-10-24
WO2001051928A1 (en) 2001-07-19
US20010049114A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
DK1247097T3 (da) Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi
DK0960558T3 (da) Fremgangsmåder til frembringelse af udbyttekort
NO20024562L (no) Seismiske kildegrupper
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
NO20032447L (no) System for ultrasonisk testing
NO20023705L (no) Bestemmelse av art/type for et underjordisk reservoar
DE10328828A8 (de) Vermessungssystem
PT103029B (pt) Inibidores de dopamina-beta-hidroxilase selectivos perifericamente e metodo paraa sua preparacao
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
DE60212776D1 (de) Spezifisches Bindungsanalyseverfahren
NO20030937L (no) Kreatin-ester pronutrient forbindelser og utforminger
NO20020780D0 (no) Bildeanalyse
DE50103892D1 (de) Navigationsverfahren
NO20030751D0 (no) Sensor for seismisk kilde
DE60131665D1 (de) Vorrichtung zur mikrostromtherapie
AT500412B8 (de) Flüssigmetall-ionenquelle
DE60207833D1 (de) Peptiddeformylase-hemmer
DK1372607T5 (da) Adjuvans-emulsion og fremgangsmåde til anvendelse af nævnte emulsion
IS7441A (is) Peptíðdeformýlasatálmar
ITBO20000398A0 (it) Tozzetto e metodo per la sua realizzazione .
DE60229515D1 (de) Ionenstrahl vorrichtung
DE60232650D1 (de) Peptiddeformylaseinhibitoren
DE60305102D1 (de) Vorrichtung zur Auswahl von bimetallischen Münzen
DE59904759D1 (de) Vorrichtung zum temporären lagedefinierten fixieren von lichtleiterenden
SE0200215D0 (sv) An analysis system